| 2018-12-10 08:09:04|
PFNX, LLY 08:09 12/10 12/10/18
Pfenex submits PF708 NDA to FDA
Pfenex (PFNX) announced the submission of its new drug application, or NDA, to the FDA seeking approval of PF708 for the treatment of osteoporosis. The application is submitted as a 505 NDA and references Eli Lilly's (LLY) Forteo as the reference listed drug.